entertainment -WSS

entertainment

author：explore 2025-10-01 04:10:18 - browse：5683

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： BioAge raises $170M for combination therapy with Zepbound

focus

WSS

Biden report: The neurospychology of memory and aging

WATCH: Why do fingernails fall off when they're damaged?

Biogen Alzheimer’s drug launch off to slow start

What should King Charles tell the public about his cancer?

Readout LOUD podcast: How biotech is using artificial intelligence

STAT's guide to the next generation of CAR

Wikipedia

entertainment

knowledge

Medical records are filled with copy

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Hollywood unions extend contract negotiations for actors

Why did Pfizer dish out millions for a Super Bowl ad?

Novavax promises a turnaround & Lilly roils the obesity market

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

How to save PrEP access — and even expand it

Robert F. Kennedy is pitching centrism on health, even on abortion

After affirmative action ruling, medical educators look to 'holistic review'

Medical mystery: When a cough is not just a cough

focus

A disappointing year of Humira biosimilars

New guidelines on severe brain injury complicate already difficult decisions

Medical mystery: When a cough is not just a cough

A disappointing year of Humira biosimilars

KalVista pill reduced swelling 'attacks' caused by genetic disease

What should King Charles tell the public about his cancer?

focus

focus

focus

focus